Know Cancer

or
forgot password

Prostate Localization During Radiotherapy Using a Ni-Ti Stent and Electronic Portal Imaging – Protocol II


Phase 1
N/A
N/A
Open (Enrolling)
Male
Prostatic Neoplasms

Thank you

Trial Information

Prostate Localization During Radiotherapy Using a Ni-Ti Stent and Electronic Portal Imaging – Protocol II


Inclusion criteria’s in the study were 1) Patients should present with histological verified
local or locally advanced PC (stage T2b to T3b, N0, M0; UICC 1992 classification was used).
2) Patients should consequently be candidates for intended curative radiotherapy. Prostatic
work up is done before inclusion in the study. A new prostatic Nickel - Titanium stent is
placed in the prostatic urethra one week prior to the radiotherapy planning CT using a
flexible cystoscope to insert the stent under urethral anaesthesia. The stent is then
flushed with hot water (60 degrees Celsius). The hot water expands the stent collar, thereby
locking the stent in place. Correct positioning of the stent is secured visually on
retraction of the scope. Radiotherapy of prostate is given to a mean dose of 70 (department
standard regime). Treatment are given with daily fractions of 2 Gy using a combination of 6
MV and 18 MV X-ray fields using isocentric 3D conformal treatment plan, consisting of three
MLC conformal radiation fields (One anterior and two lateral wedged fields). This was
assumed to be the optimal treatment plan. A pair of orthogonal 15 cm x 15 cm isocenter setup
fields was added to the plan. The orthogonal fields are used to obtain pairs of electronic
portal images. Electronic portal images are recorded using a Varian As500 electronic portal
imaging device (EPID). The images are used to determine the 3D reference position of the
stent. The image pairs of the stent were taken at eight treatment sessions in each patient
(Session number 1,2,3,6,11,21,22 and 23). From each orthogonal set of images the 3D position
of both the stent and the symphysis (pubic bone) are determined. Positions are calculated
using orthogonal reconstruction. A control CT scan is made before treatment session number
21 to verify the intra prostatic position of the stent. The intra prostatic position of the
stent is also verified during removal of the stent three months after radiation therapy.
Before removal the stent was flushed with water at 10 degrees Celsius. When cooled with 10°C
cold water, the stent became super soft, and can easily be removed as a twisted wire.


Inclusion Criteria:



1. Patients should present with histological verified local or locally advanced PC
(stage T2b to T3b, N0, M0; UICC 1992 classification was used).

2. Patients should consequently be candidates for intended curative radiotherapy -

Exclusion Criteria:

dislocation or removal of stent

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

stent in situ during radiotherapy

Principal Investigator

Jesper Carl, PhD

Investigator Role:

Study Chair

Investigator Affiliation:

Dept medical Physics, Oncology

Authority:

Denmark: National Board of Health

Study ID:

stent02

NCT ID:

NCT00250224

Start Date:

January 2006

Completion Date:

December 2006

Related Keywords:

  • Prostatic Neoplasms
  • Radiotherapy
  • image guided
  • marker
  • Neoplasms
  • Prostatic Neoplasms

Name

Location